IE85516B1 - Enriched milk products - Google Patents
Enriched milk products Download PDFInfo
- Publication number
- IE85516B1 IE85516B1 IE2006/0795A IE20060795A IE85516B1 IE 85516 B1 IE85516 B1 IE 85516B1 IE 2006/0795 A IE2006/0795 A IE 2006/0795A IE 20060795 A IE20060795 A IE 20060795A IE 85516 B1 IE85516 B1 IE 85516B1
- Authority
- IE
- Ireland
- Prior art keywords
- milk
- period
- days
- ungulate
- milking
- Prior art date
Links
- 210000004080 Milk Anatomy 0.000 title claims description 117
- 235000013336 milk Nutrition 0.000 title claims description 117
- 239000008267 milk Substances 0.000 title claims description 114
- 229940078795 Lactoferrin Drugs 0.000 claims description 53
- 102000010445 Lactoferrin Human genes 0.000 claims description 53
- 108010063045 Lactoferrin Proteins 0.000 claims description 53
- 235000021242 lactoferrin Nutrition 0.000 claims description 53
- 239000000843 powder Substances 0.000 claims description 16
- 230000006651 lactation Effects 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 235000013351 cheese Nutrition 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 235000021119 whey protein Nutrition 0.000 claims description 5
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 102000000119 Beta-lactoglobulin Human genes 0.000 claims description 3
- 108050008461 Beta-lactoglobulin Proteins 0.000 claims description 3
- 102000014171 Milk Proteins Human genes 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 3
- 235000021239 milk protein Nutrition 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 240000002129 Malva sylvestris Species 0.000 claims description 2
- 235000006770 Malva sylvestris Nutrition 0.000 claims description 2
- 235000010703 Modiola caroliniana Nutrition 0.000 claims description 2
- 235000014048 cultured milk product Nutrition 0.000 claims description 2
- 235000019541 flavored milk drink Nutrition 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 235000020124 milk-based beverage Nutrition 0.000 claims description 2
- 235000008939 whole milk Nutrition 0.000 claims description 2
- 206010022000 Influenza Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 239000005862 Whey Substances 0.000 description 7
- 235000013365 dairy product Nutrition 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- -1 WMP Substances 0.000 description 3
- 229940072440 bovine lactoferrin Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- 210000003022 Colostrum Anatomy 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 229940057428 LACTOPEROXIDASE Drugs 0.000 description 1
- 102000028880 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 208000004396 Mastitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 240000008214 Trifolium repens Species 0.000 description 1
- 235000013540 Trifolium repens var repens Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003385 bacteriostatic Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000020243 first infant milk formula Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000027739 mammary gland involution Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Description
Field of the Invention The present invention relates to a method for producing lactoferrin-enriched milk ptotlucts. and to milk products produced by the methods.
Background Art Lactofcnin is :1 component of milk whey. valuable for many biological properties, including those as an iron-binding, bacteriostatic and anti-bacterial protein. Commonly, lactoferrin concentrations are high in colostrum (Nonnecke & Smith, 1984, J Dairy Science 62. 286%-72). In particular, the lactoferrin content of mammary secretion is markedly increased during mammary involution when expression of the lactoferrin gene is initiated in niilk-engorged secretory alveoli (Molenaar er al.. 1996 J Dairy Research 60: I -l l).
The process of mammary gland involution occurs during the transition from a lactating to a non~|actating state. This transition phase begins after cessation of milk removal and results in changes in mammary secretion composition. Secretion volume declines during involution, as does the concentration of most milk—specif1c components. Lactoferrin. hydrolytic enzymes, immunoglobulins, and serum-derived components increase in concentration in the secretions during involution (Hurley WL 1989, J Dairy Sci.
It has also been shown that once-daily milking results in an increase in the concentration of lactoferrin, however lactoferrin concentration slowly declined following the resumption of twice-dai Iy milking (Fan et al., 2002 Proceedings of the New Zealand Society of Animal Production 62: 225-236).
It would be beneficial to establish a milking regime which would result in a significant increase in lactoferrin yield, that is a regime in which increased lactoferrin concentration is achieved whilst milk yield is maintained. Milk products derived from such milk and/or laclolet‘i'in isolated from the milk would be useful due to the beneficial properties of lactol‘erri n discussed above.
[I is .-in object of the invention to provide a method for the production of lactofenin— enriched milk products and/or at least to provide the public with a useful choice.
Summary of the Invention The applicants have shown, for the first time. that it is possible to re-establish milking after an extended period of non-milking. and at the same time to maintain a several-fold elevation in the concentration of lactofemn in the milk for a significant period after milk production is reestablished. Using the procedure established by the applicants, commercial quantities of lactoferrin-enriched milk can be harvested over a period of a few days and can be processed to produce a lactoferrin emiched milk product.
In one aspect the invention provides a method of producing a lactofemnenriched milk product comprising the steps of: I ) providing a milk sample prepared by a) ceasing to milk a ungulate for a period of greater than 24 hours: b) collecting milk from the ungulate within 21 petiod of up to 7 days after completion of a); and ) processing the milk sample to produce a milk product.
In one embodiment the method comprises the steps of: at ceasing to milk an ungulate for a period of greater than 24 hours; b) collecting milk from the ungulate within a period of up to 7 days after completion of a); and C) processing the milk collected to produce a milk product.
Preferably the ungulate is a cow or a goat. More preferably the ungulate is a cow.
In one embodiment the cow is in late lactation (within 90 days of the next calving). in a further embodiment the period in a) is at least 2 days. preferably at least 3 days, more preferably at least 4 days, more preferably at least 5 days, most preferably at least 6 days.
In it fttttltct embodiment prior to step 21) the ungulate is subjected to once daily milking fol st period of at least 2 days.
In 3-] further embodiment the period in b) is less than 7 days, alternatively less than 6 days, alternatively less than 5 days, altematiyely less than 4 days. ln a preferred embodiment the ungulate is milked twice daily during the period in b) Prefcrabl y the level of lactofeirin in the milk collected is at least 400 mg/l. more prcferabl y at least 600 mg/L more preferably at least 800 mg/l, more preferably at least 1000 mg/I. tnore preferably at least 1500 mg/1, more preferably at least 2000 mg/l. more preferably at least 2500 mg/I, more preferably at least 3000 mg/l, more preferably at least 3500 mg/I, more preferably at least 4000 mg/1, more preferably at least 4500 mg/l. more preferably at least 5000 mg/I, most preferably at least 5000 mg/l.
To obtain lactoferrin concentrations greater than 1500 mg/l it is generally necessary to select high lactoferrin producing ungulates.
In a further embodiment the ungulate used in the method produces milk relatively low in beta-lttctoglobulin concentration under standard milking conditions. Preferably the ungulate is a cow identified by the BB beta-lactoglobulin genotype (Hill, JP 1993. Journal of dairy science 76. 281-286) or other genetic or laboratory tests. Use of such cows in the method would enable production of whey protein concentrate (W PC) containing an even greater proportion of lactofenin.
The milk product may be a milk powder including whole milk powder (WMP) and skimmed milk powder tSMP)_, a milk protein concentrate (MPC) or a whey protein concentrate (WPC).
The milk product may be a food product.
The milk product may be a nutritional supplement.
Alternatively the milk product may be lactoferrin isolated from the milk.
Ix) JJI The mill product may also be a milk product to which the isolated lactoteirin is added.
In a further aspect the invention provides a milk product produced by the method of the invent ion.
In it further aspect the invention provides a nutritional supplement containing a milk product of the invention.
In a further aspect the invention provides a food product containing a milk product of the invention.
Detailed Description of the Invention Definitions The term “once daily milking” means milking the ungulate once within a twenty-four hour period.
The term “twice daily milking” means milking the ungulate twice within a twenty-four period.
The term "milk protein concentrate" or “MPC" means a powder formed from the concentration of milk, usually comprising 55-85% protein and manufactured via filtration. evaporation. and drying.
The term "whey protein concentrate” or “WPC" means a powder formed from the concentration of whey proteins. comprising at least 50% protein and manufactured from whey via filtration, evaporation, and drying.
The term “food product” as used herein includes solid foods, liquid beverages and other edible materials regardless of their specific form.
Ix) LII ’l‘|n-, torn: "coitipt'ising" as used in this specification and claims means “consisting at least in part of‘: that is to say when interpreting statements in this specification and claims which include "comprising”, the features prefaced by this term in each statement all need to be present but other features can also be present. Related temrs such as “eornpiise” and “conrpriserl“ are to be interpreted in similar manner.
In this specification where reference has been made to patent specifications. other extemal documents. or other sources of information, this is generally for the purpose of providing a Context for discussing the features of the invention. Unless specifically stated otherwise, reference to such extemal documents is not to be construed as an admission that such documents. or such sources of information, in any jurisdiction, are prior art. or form part of the common general knowledge in the art.
The Applicants have discovered that following a period of non-milking of greater than 24 hours followed by a resumption of milking, the concentration of lactoferrin in milk collected is significantly increased and surprisingly that the increased concentration is maintained while milk production recovers for a period of at least four days resulting in an increased yield of lactoferrin in milk collected during this period.
The invention provides methods for producing lactoferrin enriched milk products, milk, milk powder, WMP, SMP, MPC and WPC nutritional supplements and food products.
Methods for preparing milk powder, WMP, SMP, MPC, WPC are known to those skilled in the art (Encyclopaedia of Dairy Sciences 2003, Eds Roginskj, H., Fuquay. J.W. Fox.
P.I~‘. and Academic Press and references cited therein). Further, it is well known that, to avoid losses of lactoferrin during manufacture of milk powders, it is necessary to carefully regulate temperature during spray drying and also the pH and ionic strength of the milk or milk fraction. It is known to those skilled in the art that to avoid denaturation of lactoferrin, steps requiring heat treatment should preferably be performed with the laetoferrin in a low ionic strength solution. The relationship between the temperature and ionic strength is discussed in European Patent Application 0364912 which is incorporated herein by reference. Low ionic strength may be effected by way of dialysis. Ultrafiltration, diafiltration, resuspension of dried material in a suitable solution, or other methods known to those skilled in the art.
In one embodiment, the processing of the milk or milk sample is processing to isolate lactoferrin. Preferably lactoferrin is isolated by ion exchange chromatography, preferably cation exchange. Preferably ion exchange is carried out at neutral pH. Preferably ion exchange is carried out using column chromatography. In one embodiment a membrane adsorber. that immobilises the exchange functional groups on a microporous membrane, is used for ion exchange Preferably lactoferrin is extracted from whey using a strongly acidic membrane adsorber.
Examples of methods for isolating lactofenin from milk are found in New Zealand Patent Numbers 221082, 227097, 249235, in US Patent numbers 4,791,193 and 5,596, 082. and in Mitchell et al. I994. Extraction of lactoperoxidase and lactoferrin from cheese whey using membrane cation exchangers. Page 89 in DDF Seminar: Indigenous Antimicrobial Agents of Milk — Recent Developments Int. Dairy Fed., Brussels, Belgium.
Methods for pasteuiising lactoferrin containing solutions as described in European Patent Application 0364912.
Methods for incorporating milk powder, WMP, SMP, MPC, WPC or lactoferrin into nutritional supplements and food products are known to those skilled in the art.
Preferred food products include dairy products such as milk drinks (including treated milks such as skimmed milk and consumer products such as flavoured milks), fermented milk products (including yoghurts and cheeses), and milk preparations (including infant milk formulas and products made using milk powders or milk components as ingredients).
Brief Description of the Drawings Figure 1 shows change in milk yield during resumption of milking after a 2-day (0) or a 4- day (3) milking interval in cows (n=10 per group) at the end of lactation. Pre-treatment yields are shown at day -4. Error bars are standard error of mean. Horizontal bars indicate duration of iionmilking period.
Figure 3 shows change in milk lactofeirin concentration during resumption of milking after :1 2-day (6') or 21 4-day (ax) milking interval in cows (n=l0 per group) at the end of lactation.
Prc-treatment concentrations are shown at day 4.
Figure 3 shows change in milk lactoferrin yield (g/d) during resumption of milking after a 2-day (9) or ‘:1 4-day (to) milking interval in cows (n=l0 per group) at the end of lactation.
Pre-treatment yields are shown at day -4. Note sustained, elevated yields 2-4 days after milking was resumed.
Figure 4 shows cumulative milk yield and lactoferrin yield over 4-days after resumption of milking after 21 2-day (0') or a 4-day (mi) milking interval in cows (n=l0 per group) at the end of lactation.
Figure 5 shows lactofenin concentrations, n=6 per group (mg/ml) in milk at each milking after resumption of milking following 2. 4 or 7 days without milking in mid~lactation.
Data at milking ~l show the pre-treatment milk lactoferrin concentrations and at milking 0 at the first milking after the non-milking period. Milking 6 was a composite am + pm sample. as was milking 7. Hence the data presented covers a total of 10 milkings post- treatment.
Figure 6 shows changes in milk yield (kg/day) following cessation of milking in mid- lactation. First point at day -1 is the yield during twice-daily milking. The second point at time 0 is the accumulated volume of secretion during the non-milking period (2. 4 or 7 days —see legend). Thereafter, yields are for 24 h periods. Average yields are shown for 12 cows per group.
Figure 7 shows daily lactoferrin yields, n=6 per group (g/d). Day -1 represents daily yield before treatment and day 0 is the yield at the first milking after 2, 4 or 7 days without milking in mid—|actation.
Examples l\J VJ} The iiwention will now be illustrated with reference to the following non-limiting examples.
Example I: Milking regime resulting in increased yield of lactoferrin from cows in late lactation.
Twenty cows. grazing good quality pasture. in late-lactation, free of mastitis and with an average milk yield about 9 kg/d during twice—daily milking, were not milked for 3 consecutive milkings (n=10) following a morning milking (2-day interval) or for 7 consecutive milkings (n=l0) following a morning milking (4-day interval). Milking was then resumed and continued twice daily for a further 5 days. Milk yield was measured at each milking and milk lactoferrin concentrations measured using an ELISA kitt Bethyl Laboratories. Montgomery, Texas, USA ) specific for bovine lactoferrin.
Milk yields and lactofenin concentrations in milk from the experimental cows are shown in Figures l—3. Milk yield at the resumption of milking was the accumulation of secretion during the extended interval and as such was close to the normal twice-daily yield.
However. secretion rate was suppressed by the lack of milking such that milk secretion over the first 24 hours after resumption of milking was less than 30% of previous yields on twice-daily milking (Figure l). Yield recovered to close to previous levels over the next 3 days, recovery being somewhat slower in the 4-day group.
Milk lactoferrin concentrations differed between the 2-day and 4-day treatment groups in the first milk after resumption of milking, but after 48 hours, concentrations of lactofenin in milk of both groups was elevated about four-fold compared to pre-treatment and this increase was sustained for a further 48 hours, at least (Figure 2).
Daily yield (g/day) of lactoferrin was elevated in the 4-day interval group at the resumption ol" milking but declined in both groups over the first 24 hours only to rebound to a daily secretion rate 2-3 fold greater than pre-treatment values 2-4 days after the resumption of milking and through the time period when recovery of milk yield was maximal (Figure 3). to ‘J: Data in Fi_u_ur‘e 4 show that both treatments result in accumulated secretion of about 30 litres; of mill containing 30-35g of lactoferrin in the four day period following resumption of milking.
Example 2: Milking regime resulting in increased yield of lactoferrin from cows in mid-lactation Methods This trial was undertaken in Taranaki, New Zealand in December 2004. Thirty-six cows of mixed age and breed (Jersey, Friesian) and approximately 16 weeks of lactation (J uly/August 2004 calving) and early (<2months) pregnancy were selected for the trial.
Milk from these cows tested bacteriologically negative approximately 5 days before trial began. All selected cows were producing > 8kg milk/day at the herd test on December 3'”/4"‘. Animals grazed ryegrass/white clover pasture as their sole diet. Sufficient pasture was offered to maximise feed intake.
Cows were allocated into 3 groups of 12 (‘balanced for age breed and milk yield). The cows were milked twice daily, then were not milked for 3 consecutive milkjngs (in:l2) following a morning milking (2-day interval) or for 7 consecutive milkings (n=l2) following a morning milking (4-day interval) or for 13 consecutive milkings (n=l2) following a moming milking (7-day interval). The last milking for each group was on the morning of 6”‘ December, 9"‘ December and 11"’ December for 7-day, 4-day and 2-day groups respectively. They were then re-milked (twice daily) and recovery of milk yield and composition monitored for the next 5 days (or longer for some parameters).
Mi/It xmnplex Milk saniples were collected at the pre-tnal herd test and at every milking following the resumption of milking for 3 days. Thereafter, composite samples of atn and pm milk were taken fora further 2 days.
Milk um1lg\~‘.s‘c.r i.,actoi‘erriii coricentrations were determined in the milk samples using :1 lactoferrin ELISA kit tliethyl Laboratories, Montgomery. Texas, USA). Milks from 6 cows in each group were anal ysetl.
Results All groups showed elevation of milk lactoferrin concentration for at least 7 milkings (3-4 days) after the restart of twice—daily milking following cessation of milking for 2. 4 or 7 days (Figure 51. Maximal concentrations were obtained at around milking 3 following the restart, representing a 4-5 fold increase in lactoferrin concentration yield. Elevated lactoferrin concentrations were still apparent at milking 7.
Milk yield recovered rapidly with the resumption of milking and was fully recovered by day 4 in the 2 and 4 day groups ( Figure 6). Milk yield recovery was slower in the 7-day group but yield was close to the 2 and 4-day groups by day 7 following the resumption of milking.
Calculation of lactoferrin yields indicate that daily production of lactoferrin was stimulated 2-4 fold by the non—milkjng treatment especially in the 2 and 4-day groups. (‘Figure 7).
Example 3: Purification of Lactoferrin from the lactoferrin-enriched milk Lactoferrin can be purified, from milk produced by the method of the invention. using the method of US 5.596.082.
Milk produced by the method of the invention is used to produce a clarified cheese whey having a solids content of 5.6% and a pH of 6.6. by cross-flow microfiltration 1.4 .mu.m (Alfa Laval).
A column having a diameter of 1.6 cm is packed with 20 ml of the strong cation exchanger 3 Sepharose Big Beads (Pharmacia). The bed height is 10 cm. After equilibration of the resin with 0.0‘25M phosphate buffer pH 6.5, the clarified cheese whey is pumped through the column at a rate of 150 or 200 bed volumes/hour Alter Wil:x'l’Iillg oi’ the column with buffer, LP is eluted in with 0.8M NaCl in pliosphate bullet.
The eluates may be freeze dried.
Example 4: Purification of Lactoferrin from lactoferrin-enriched milk at pilot production scale A ll) cm column of a pilot production chromatography system (Bioprocess System Pharmacia) is packed with SP Sepharose Big Beads (Pharmacia). The diameter of the column is 10 cm, the bed height is 11 cm and the bed volume is 0.864 1.
After equilibration of the resin at room temperature with 0.025M phosphate buffer pH 6.5. clarified cheese whey, prepared as described in Example 3, is pumped through the column at Ll rate of flow of 180 litrefhour.
After washing of the column with buffer solution. lactoferrin is eluted with 1.0M NaCl in phosphate buffer. The liquid flow rate during washing and elution was 8.6 litre/hour (10 bed volumes/hour).
The cluates may be freeze dried.
Example 5: Pasteurization of lactoferrin Freeze—dried lactoferrin-enriched milk powder. produced from milk produced by the method of the invention, can be pasteurised using the method of EP 0344912. g of a freeze—dried bovine lactoferrin powder is dissolved into I litre of deionized water. This aqueous lactofenin solution is placed in a vessel with a lid, and is heated in hot water at 85°C for 30 minutes. After the heating, the aqueous lactoferrin solution is immediately cooled to room temperature with running water.
Example 6: Large scale purification and pasteurisation of lactoferrin Ten tonnes of raw skim milk, obtained by standard procedures from milk produced by the method of the invention. is passed through a C3.lTl€l‘ comprising chitosan beads to which sulphuric ester is attached. Bovine lactoferrin which is absorbed onto the beads, washed then eluted with a 1 M saline solution. The eluate is desalted/concentrated through an ultrafilter (DDS 20), so that 20 litres of a lactoferrin solution are obtained. The solution is then pasteurized by heating at a temperature of 95°C for 4 seconds by the use of a plate type heal-exchanger, and then cooled to 7°C.
The above Examples illustrate practice of the invention. It will be appreciated by those skilled in the art that numerous variations and modifications may be made without departing from the spirit and scope of the invention.
Claims (9)
1. Claims: I . A method of producing a lactofemh-enriched milk product comprising the steps of: I ) providing a milk sample prepared by 21) ceasing to milk an ungulate for a period of greater than 24 hours; b) collecting milk from the ungulate within a period of up to 7 days after completion of a); and
2. ) processing the milk sample to produce a milk product. 2. The method of claim 1 comprises the steps of: :1) ceasing to milk an ungulate for a period of greater than 24 hours; bl collecting milk from the ungulate within a period of up to 7 days after completion of a); and c) processing the milk collected to produce a milk product.
3. The method of claim 1 or claim 2 wherein the ungulate is in late lactation (within 90 days of the next calving). . The method of any preceding claim in which the period in a) is at least 2 days. 5. The method of any preceding claim in which the period in a) is at least 3 days. 6. The method of any preceding claim in which the period in a) is at least 4 days. 7. The method of any preceding claim in which the period in a) is at least 5 days. 8. The method of any preceding claim in which the period in a) is at least 6 days. 9. The method of any preceding claim in which the period in a) is at least 7 days. I0. The method of any preceding claim in which the period in a) is at least 8 days. l 3. "Flu; method of any preceding claim in which, prior to step a), the ungulate is subjected to once daily milking for a period of at least 2 days. I2. The method of any preceding claim in which the period in b) is less than 7 days. I3. The method of any preceding claim in which the period in b) is less than 6 days I
4. The method of any preceding claim in which the period in b) is less than 5 days. IS. The method of any preceding claim in which the period in b) is less than 4 days. I6. The method of any preceding claim in which the ungulate is milked twice daily during the period in b). I7. The method of any preceding claim in which the level of lactoferrin in the milk collected is at least 400 mg/l. I8. The method of any preceding claim in which the ungulate used in the method produces milk relatively low in beta-lactoglobulin concentration under standard milking conditions. l9. The method of claim 18 in which a ungulate is a cow identified by the BB beta- lactoglobulin genotype. 20. The method of any one of claims I to 19 in which the milk product is selected from a group consisting of a milk powder (including whole milk powder [WMP] and skimmed milk powder [S MP]), :1 milk protein concentrate (MPC) and a whey protein concentrate (WPC). 21. The method of any one of claims 1 to 19 in which the milk product is a food product. 22. The method of claim 21 in which the food product is selected from a group consisting of milk drinks {including treated milks such as skimmed milk and consumer products such as flavoured milks). fermented milk products (including yoghuns and cheeses), and milk prepnation.-3 (including infant milk formulas and products made using milk powders or milk components as ingredients). 23. The method any one ofclaims I to 19 in which the milk product is a nutritional supplement. 24. The method of any one of claims 1 to 19 in which the milk product is lactofenin isolated from the milk. 2
5. The method of any preceding claim in which the milk product is a milk product to which the lactofenin of claim 24 is added. 2
6. The method of any preceding claim in which the ungulate is a goat or a cow. 2
7. The method of claim 25 in which the ungulate is a cow. 2
8. A milk product produced by the method of any preceding claim. '2
9. The method of any one of claims 1 to 19 and 24 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USUNITEDSTATESOFAMERICA28/10/20056 | |||
US73116805P | 2005-10-28 | 2005-10-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE20060795A1 IE20060795A1 (en) | 2007-05-30 |
IE85516B1 true IE85516B1 (en) | 2010-05-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Walstra et al. | Dairy science and technology | |
US4834974A (en) | Immunologically active whey fraction and recovery process | |
US11116233B2 (en) | Process for producing infant formula products and acidic dairy products from milk | |
Fox et al. | Whey and whey products | |
EP3496543B1 (en) | Process for producing infant formula products and dairy products | |
Ramos et al. | Whey: generation, recovery, and use of a relevant by-product | |
CA2217820C (en) | Milk and milk products for preventing or treating heart disease | |
AU2006233196B2 (en) | Enriched milk products | |
CN101014253A (en) | Human milk fortifiers and methods for their production | |
JP6124420B2 (en) | Fermented milk and method for producing the same | |
JP6124419B2 (en) | Fermented milk and method for producing the same | |
Aslam et al. | Recent Developments in Purifi cation Techniques for Whey Valorization | |
IE85516B1 (en) | Enriched milk products | |
EP0595993A1 (en) | Isolation of charged particles from fluids | |
Echegaray et al. | Dairy by-products as source of high added value compounds: Conventional and innovative extraction methods | |
Mulvihill et al. | Production of whey-protein-enriched products | |
JP3411965B2 (en) | Method for producing polyamine-containing composition | |
US20240188579A1 (en) | Whey protein-containing product enriched in immunoglobulins | |
RU2793288C2 (en) | Method of producing baby food and fermented milk products from milk | |
JP6562958B2 (en) | Fermented milk and method for producing the same | |
AU2004206984B2 (en) | Bovine genotype testing for beta-caseins | |
US20020007497A1 (en) | Food product and process | |
NZ306584A (en) | Milk or dairy products derived from animals and which are free of beta casein |